latest news releases from the newsroom
Astex Reveals Structure of Key Drug Metabolizing Enzyme -- Cytochrome P450 3A4 -- in Science
CAMBRIDGE, United Kingdom, July 16, 2004 (PRIMEZONE) -- Astex Technology, the fragment-based drug discovery and development company, today announced that its scientists had published the 3-dimensional structure of human cytochrome P450 3A4, the most important drug metabolising enzyme. The crystal structure of the protein is reported in the leading science journal Science(1). This is the first time this structure has been published and follows another world first when Astex published in Nature(2) the first 3-dimensional crystal structure of a human cytochrome P450 protein, CYP450 2C9. CYP450 3A4 is one of four key enzymes that are responsible for metabolizing more than 90% of drugs and cause significant attrition in the drug development process.
Ahold resolves pending litigation with AIG
ZAANDAM, The Netherlands, July 16, 2004 (PRIMEZONE) -- Ahold today announced that it has settled all pending insurance coverage litigation with AIG Europe (Netherlands) N.V. regarding the directors and officers liability insurance policy for Ahold and its subsidiary U.S. Foodservice. Under the terms of the settlement announced today, the lawsuit filed by AIG in the District Court of Haarlem, The Netherlands and the lawsuit filed by U.S. Foodservice in the United States District Court for the District of Maryland (Northern Division) will both be terminated. No other terms or conditions of the settlement were disclosed.
Port of Houston Authority
PHA Commission Considers Bayport, Security, Capital Development, and Public Affairs Matters
HOUSTON, July 15, 2004 (PRIMEZONE) -- The Port of Houston Authority (PHA) commission will consider several recommendations involving contract awards, bids and proposals, professional services and general administrative and operational matters during its public meeting at 2 p.m. on Monday, July 19, 2004 in the 4th floor board room at 111 East Loop North (exit 29 off Loop 610). Chairman Jim Edmonds will preside over the meeting to be attended by Vice Chairman Kase Lawal, Commissioner Steve Phelps, Commissioner Jim Fonteno, Commissioner Jimmy Burke, Commissioner Cheryl Thompson-Draper, and Commissioner Janiece Longoria.
Toll Brothers, Inc.
Toll Brothers Announces New $1.05 Billion Bank Credit Facility
HUNTINGDON VALLEY, Pa., July 15, 2004 (PRIMEZONE) -- Toll Brothers, Inc. (NYSE:TOL), the nation's leading builder of luxury homes, today announced the completion of a new $1.05 billion unsecured bank revolving credit facility. The new facility, which matures in 2009, replaces Toll Brothers' previous $575 million facility. It has an accordion feature under which it can grow up to $1.2 billion, subject to the availability of additional bank commitments.
Penn's Landing Corporation
WXPN Singer Songwriter Weekend: A Community Celebration of Musical Discovery
PHILADELPHIA, July 15, 2004 (PRIMEZONE) -- For 11 years, the Independence Blue Cross WXPN Singer Songwriter Weekend has presented an amazing music festival featuring heritage artists, new acts, and local performers. It is one of the premier music events in Philadelphia, drawing thousands of people to Penn's Landing for two days of great music. A celebration of the public radio station's community of passionate music fans, the WXPN Singer Songwriter Weekend showcases the best singer songwriters in the nation. This year, the festival starts early with the addition of a Friday night line up.
ProtoKinetix Reports on Potential of AFGP as Well as Progress Made on the AFGP Transaction
VANCOUVER, British Columbia, July 15, 2004 (PRIMEZONE) -- On June 28, 2004, ProtoKinetix (OTCBB:PKTX) announced that it had reached an agreement with Perigene, Inc. to acquire a patented antifreeze glycoprotein technology. Dr. Todd commenting on the progress on the acquisition of the AFGP technology stated, "Both ProtoKinetix and Perigene are in the process of conducting due diligence. Thus far, the AFGP technology appears to be exactly what it was represented to be. The initial executed agreement, which was approved by the Perigene board of directors, calls for a due diligence period. ProtoKinetix believes that the two companies will be able to reach a set of final negotiated terms within the next 10 days. The final negotiated terms will be memorialized in a Final Agreement. ProtoKinetix believes that the transaction should ultimately close within 30 days."